Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Irinotecan 31Paclitaxel 27Gemcitabine 27Cisplatin 25Docetaxel 20Oxaliplatin 16Fluorouracil 15alvocidib 13Leucovorin 13Carboplatin 13Capecitabine 12Bortezomib 10Early Intervention, Educational 9Topotecan 8Taxes 8Bevacizumab 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7ixabepilone 6Vorinostat 6Temozolomide 6Sorafenib 6Immunohistochemistry 6Immunoenzyme Techniques 67-hydroxystaurosporine 6tanespimycin 5Pharmacogenomic Testing 5Pemetrexed 5Magnetic Resonance Spectroscopy 5Filgrastim 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unspecified Adult Solid Tumor, Protocol Specific × soblidotin × Clear all
NCT00072228 2013-07-10

Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1 Withdrawn
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡